Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic - Current Oncology Reports
Source : https://link.springer.com/article/10.1007/s11912-022-01198-z
Purpose of Review Chronic lymphocytic leukemia (CLL) is the most frequent lymphoproliferative disease in the elderly of the western world. Immune defective responses and treatment can worsen the immune system's...
Summary: CLL patients are at a greater risk of death from COVID-19. Inherent immunosuppression of CLL and immune deficiencies caused by treatment significantly decrease the ability to produce natural or vaccine-induced anti-SARS-CoV-2 immune responses.
BTK Inhibitors Impair Humoral and Cellular Responses to Recombinant Zoster Vaccine in CLL - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35157769/
2022 Feb 14;bloodadvances.2021006574. doi: 10.1182/bloodadvances.2021006574. Online ahead of print. 1 Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, United States. 2 Department of Medicine, University of...
Relevance: Vaccinations effectively prevent infections; however, patients with chronic lymphocytic leukemia (CLL) have reduced antibody responses following vaccinations. Combined humoral and cellular immune responses to novel adjuvanted vaccines are not well characterized in CLL. In an open-label, single-arm clinical trial, we measured the...
The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35159041/
The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the management and clinical history of patients with chronic lymphocytic leukemia (CLL). BTK is a critical molecule that interconnects B-cell...
Relevance: This review summarizes the pharmacology, clinical efficacy, safety, dosing, and drug-drug interactions associated with the treatment of CLL with BTK inhibitors and examines their further implications.
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35143639/
Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, about half of patients experience one or more relapses, which become progressively resistant...
Relevance: Here, we focus on our experience with BRAF inhibitors in clinical trials and as off-label use in routine practice by presenting three challenging clinical cases to illustrate their management in the context of all available treatment options.
Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia
Source : https://www.futuremedicine.com/doi/10.2217/fon-2021-0602
Bruton’s tyrosine kinase inhibitors have changed the treatment landscape for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma dramatically. In 2019, acalabrutinib was approved by the US...
Relevance: Bruton’s tyrosine kinase inhibitors have changed the treatment landscape for chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma dramatically. In 2019, acalabrutinib was approved by the US FDA for the treatment of treatment-naive and relapsed/refractory CLL and MCL. Acalabrutinib...